Finance

Lists
1801:HKG
Innovent Biologics Inc
89,05 HKD
+1,48%
(+1,30) 1D
16-окт., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1801...
Open
91,25 HKD
High
92,45 HKD
Low
88,00 HKD
Mkt. cap
155,56 млд
Avg. vol.
9,91 млн
Volume
9,69 млн
P/E ratio
111,08
52-wk high
112,70 HKD
52-wk low
69,55 HKD
EPS
0,80 HKD
No. of employees
9 миң
Open
91,25 HKD
High
92,45 HKD
Low
88,00 HKD
Mkt. cap
155,56 млд
Avg. vol.
9,91 млн
Volume
9,69 млн
P/E ratio
111,08
52-wk high
112,70 HKD
52-wk low
69,55 HKD
EPS
0,80 HKD
No. of employees
9 миң
News stories
From web sources and news partners
Profile
Innovent Biologics, Inc. is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu. Wikipedia
About Innovent Biologics Inc
CEOMichael Yu
Employees8,75 миң
Founded2011-ж., 28-ноя.
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
3,54 млд
3,54 млд
4,31 млд
4,31 млд
Cost of goods sold
845,12 млн
845,12 млн
999,35 млн
999,35 млн
Cost of revenue
845,12 млн
845,12 млн
999,35 млн
999,35 млн
Research and development expenses
807,71 млн
807,71 млн
841,85 млн
841,85 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,91 млд
1,91 млд
1,86 млд
1,86 млд
Operating expense
2,72 млд
2,72 млд
2,71 млд
2,71 млд
Total operating expenses
3,56 млд
3,56 млд
3,71 млд
3,71 млд
Operating income
-19,96 млн
-19,96 млн
602,76 млн
602,76 млн
Other non operating income
45,19 млн
45,19 млн
31,56 млн
31,56 млн
EBT including unusual items
-29,10 млн
-29,10 млн
805,83 млн
805,83 млн
EBT excluding unusual items
-1,59 млн
-1,59 млн
738,07 млн
738,07 млн
Income tax expense
-18,72 млн
-18,72 млн
179,26 млн
179,26 млн
Effective tax rate
64,33%
64,33%
22,25%
22,25%
Other operating expenses
-
-
-
-
Net income
-10,38 млн
-10,38 млн
626,57 млн
626,57 млн
Net profit margin
-0,29%
-0,29%
14,54%
14,54%
Earnings per share
-
-
-
-
Interest and investment income
124,16 млн
124,16 млн
178,13 млн
178,13 млн
Interest expense
-9,17 млн
-9,17 млн
-20,46 млн
-20,46 млн
Net interest expenses
114,99 млн
114,99 млн
157,67 млн
157,67 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
140,29 млн
140,29 млн
761,42 млн
761,42 млн
Gain or loss from assets sale
-71,00 миң
-71,00 миң
1,36 млн
1,36 млн
AI content may include mistakes. Learn more
Google колдонмолору